Chronic Pain Clinical Trial
Official title:
Managing Chronic Tendon Pain by Repurposing Metformin
The purpose of the current exploratory clinical trial is to determine the effect of oral ingestion of metformin (OIM) in non-diabetic patients with chronic Achilles tendon pain. The trial has two aims; 1) to assess the effects of OIM treatment on tendon pain, and 2) to determine the effects of OIM capsules on tendon healing and repair. Twenty participants will be treated with metformin capsules for 16 weeks combined with a home exercise program. A comparison group of 20 participants will be treated with placebo tablets along with home exercise program.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | April 2025 |
Est. primary completion date | February 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 50 Years |
Eligibility | Inclusion Criteria: - Willing and able to provide informed consent for participation - Clinical diagnosis of Achilles tendinopathy - Pain disability index score of between 20 - 70 points (0-100 scale VISA-A) - Sonopalpation tenderness with tendon thickening and/or loss of fibrillary architecture. - Ability to read, speak, and understand English Exclusion Criteria: - Any intervention (corticosteroids or other orthobiologic intervention as injection) to targeted tissue within the last 6 months. - Previous Achilles tendon surgery. - Known platelet abnormality or hematological disorder. - Presence of other conditions that might affect the functional scale of the indexed limb. - Unwillingness to be randomized. - Body Mass Index (BMI) greater than 30. - Occult tear in the indexed tendon. - Systemic inflammatory disease. - Use of fluoroquinolone in the past 6 months. - Subjects must not be pregnant or breastfeeding, or planning to become pregnant or breastfeed during the course of the trial - Chronic kidney disease (eGFR <60) - Diagnosis of diabetes mellitus or elevated HbA1c at screening (> 6.5) - Unable to take an oral medication in a non crushable pill form - Taking metformin presently or within the last 6 months - History of allergy to metformin - History of lactic acidosis or elevated lactate at screening (> 2.2) - Severe Hepatic dysfunction - Currently taking a diabetic medication such as sitagliptin, saxagliptin, linagliptin, alogliptin, sitagliptin with metformin - Currently taking a Carbonic anhydrase inhibitor such as topiramate, zonisamide, acetazolamide, dichlorphenamide, methazolamide - Currently taking cimetidine |
Country | Name | City | State |
---|---|---|---|
United States | University of Pittsburgh | Pittsburgh | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
James Wang | United States Department of Defense |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Victorian Institute of Sport Assessment - Achilles (VISA-A) Score | The VISA-A is a self-administered questionnaire that asks about Achilles tendon pain, function, and activity. Scores range from 0 to 100 with a low score indicating more severe pain. | baseline, 4 weeks, 16 weeks | |
Secondary | Change in VAS score | The VAS is a self-administered questionnaire that asks about pain. Scores range from 0 to 10 with a high score indicating more severe pain. | baseline, 4 weeks, 16 weeks | |
Secondary | Change in tendon thickness | Images of the Achilles tendon in long axis will be acquired using B-mode ultrasound imaging. Maximum Achilles tendon thickness (mm) will be measured by a blinded investigator. | baseline, 4 weeks, 16 weeks | |
Secondary | Change in tendon cross-sectional area | Images of the Achilles tendon in short axis will be acquired using B-mode ultrasound imaging. Maximum Achilles tendon cross-sectional area (mm^2) will be measured by a blinded investigator. | baseline, 4 weeks, 16 weeks | |
Secondary | Change in tendon neovascularization | Achilles tendon neovascularization will be evaluated using the 5-point modified Ohberg scale:
0 - no vessels visible one vessel, mostly anterior to the tendon one or two vessels throughout the tendon three vessels throughout the tendon more than three vessels throughout the tendon |
baseline, 4 weeks, 16 weeks | |
Secondary | Change in tendon hypoechogenicity | Hypoechogenicity is indicative of disruption of the normal fibrillar structure of the Achilles tendon. Achilles tendon hypoechogenicity will be evaluated using a semi-quantitative 3-point scale:
0 - no hypoechogenicity - Heterogeneous echotexture with diffuse hypoechogenicity between fibrillar echoes and/or foci of discontinuity in collagen fibrillar echoes - Heterogeneous echotexture with discrete hypoechoic area/s of >1mm and/or presence of intrasubstance tears |
baseline, 4 weeks, 16 weeks | |
Secondary | Change in maximum number of heel raises | The subject will stand barefoot on a 10° incline board and perform heel raises at a rate of 30 Hz (2 seconds per repetition, pace provided by audible metronome), while keeping their knee straight. Subjects will be allowed to have 2 fingertips per hand at shoulder height against the wall for balance. Participants will stop when they are unable to perform any additional repetitions, or if they fail to maintain proper form. Number of repetitions will be recorded. | baseline, 4 weeks, 16 weeks | |
Secondary | Change in heel raise height | The subject will stand barefoot on a 10° incline board and perform heel raises at a rate of 30 Hz (2 seconds per repetition, pace provided by audible metronome), while keeping their knee straight. Subjects will be allowed to have 2 fingertips per hand at shoulder height against the wall for balance. Participants will stop when they are unable to perform any additional repetitions, or if they fail to maintain proper form. Maximum height of heel rise achieved during repetitions will be measured using the Calf Raise App. | baseline, 4 weeks, 16 weeks | |
Secondary | Change in heel raise work | The subject will stand barefoot on a 10° incline board and perform heel raises at a rate of 30 Hz (2 seconds per repetition, pace provided by audible metronome), while keeping their knee straight. Subjects will be allowed to have 2 fingertips per hand at shoulder height against the wall for balance. Participants will stop when they are unable to perform any additional repetitions, or if they fail to maintain proper form. Total work (body weight x total distance) will be measured using the Calf Raise App. | baseline, 4 weeks, 16 weeks | |
Secondary | Change in counter movement jump height | Subjects will stand on a single leg with their hands behind their back, bend their knee as much as desired, and jump as high as possible from flat ground. Three trials will be performed. Jump height will be determined using the My Jump2 App and the highest jump height will be utilized in further analysis. | baseline, 4 weeks, 16 weeks | |
Secondary | Change in drop counter movement jump height | Subjects will stand on a single leg on top of an 8" plyometric box, with their hands behind their back. They will be asked to "fall" down to the floor and then immediately jump as high as possible from flat ground. Three trials will be performed. Jump height will be analyzed using the My Jump2 App and the highest jump height will be utilized in further analysis. | baseline, 4 weeks, 16 weeks | |
Secondary | Change in VAS score during hopping | Subjects will be asked to complete two 2 trials of 25 single leg hops at a natural cadence similar to jumping rope (~2 jumps/second). Subjects will be asked to rate their pain during the exercise using VAS (0-10). | baseline, 4 weeks, 16 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01659073 -
Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation
|
N/A | |
Recruiting |
NCT05914311 -
Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration
|
N/A | |
Recruiting |
NCT05422456 -
The Turkish Version of Functional Disability Inventory
|
||
Enrolling by invitation |
NCT05422443 -
The Turkish Version of Pain Coping Questionnaire
|
||
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04385030 -
Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury
|
N/A | |
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05103319 -
Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
|
||
Completed |
NCT03687762 -
Back on Track to Healthy Living Study
|
N/A | |
Completed |
NCT04171336 -
Animal-assisted Therapy for Children and Adolescents With Chronic Pain
|
N/A | |
Completed |
NCT03179475 -
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
|
Phase 4 | |
Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Recruiting |
NCT06060028 -
The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain
|
N/A | |
Recruiting |
NCT06204627 -
TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain
|
N/A | |
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00983385 -
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
|
Phase 3 | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
Not yet recruiting |
NCT05812703 -
Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain
|